Profile Of Tezacaftor/Ivacaftor Combination And Its Potential In The Treatment Of Cystic Fibrosis [Erratum]
Shiferaw D, Faruqi S. Ther Clin Risk Manag. 2019;15:1029–1040.Following a review of our paper post-publication, we found an error had been introduced during the typesetting process.On page 1029, the first sentence of the introduction section reads as “C...
Saved in:
Main Authors: | Shiferaw D (Author), Faruqi S (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2019-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Profile of tezacaftor/ivacaftor combination and its potential in the treatment of cystic fibrosis
by: Shiferaw D, et al.
Published: (2019) -
Cystic fibrosis: desensitization in delayed hypersensitivity reactions to elexacaftor/tezacaftor/ivacaftor
by: L. Gómez-Ganda, et al.
Published: (2024) -
Efficacy and Safety of Elexacaftor-Tezacaftor-Ivacaftor in the Treatment of Cystic Fibrosis: A Systematic Review
by: Nikoletta Kapouni, et al.
Published: (2023) -
Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022) -
Efectividad de TEZACAFTOR/IVACAFTOR+IVACAFTOR en fibrosis quística
by: Paula Del Río Ortega
Published: (2022)